Equillium Inc Market Cap ($89.41 Million)
Market Cap & Net Worth: Equillium Inc (EQ)
Equillium Inc market cap. Equillium Inc (NASDAQ:EQ) has a market capitalization of $89.41 Million ($89.41 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19418 globally and #4478 in its home market, demonstrating a 12.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Equillium Inc's stock price $1.41 by its total outstanding shares 63408082 (63.41 Million). Also see Equillium Inc (EQ) cash flow conversion for how efficiently the company converts equity into cash flow.
Equillium Inc Market Cap History (2018–2026)
Equillium Inc market cap history from 2018 to 2026. Data shows change from $517.41 Million to $89.41 Million (-24.77% CAGR). Check latest Equillium Inc stock price today for real-time trading data and today's change.
Index Memberships
Equillium Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #542 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1860 of 3165 |
Weight: Equillium Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Equillium Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Equillium Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Equillium Inc (EQ) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
756.02x
Equillium Inc's market cap is 756.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $67.21 Million | $15.76 Million | -$62.43 Million | 4.27x | N/A |
| 2023 | $45.84 Million | $36.08 Million | -$13.34 Million | 1.27x | N/A |
| 2024 | $47.44 Million | $41.09 Million | -$8.07 Million | 1.15x | N/A |
| 2025 | $98.28 Million | $130.00K | -$22.40 Million | 756.02x | N/A |
Competitor Companies of EQ by Market Capitalization
Companies near Equillium Inc in the global market cap rankings as of November 4, 2026. Also see Equillium Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Equillium Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Equillium Inc (2018–2026)
Market capitalization of Equillium Inc from 2018 to today. Between 2018 and today, Equillium Inc's market cap moved from $517.41 Million to $ 89.41 Million, with a yearly change of -24.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $89.41 Million | -9.03% |
| 2025 | $98.28 Million | +107.16% |
| 2024 | $47.44 Million | +3.49% |
| 2023 | $45.84 Million | -31.79% |
| 2022 | $67.21 Million | -71.88% |
| 2021 | $239.05 Million | -29.53% |
| 2020 | $339.23 Million | +58.28% |
| 2019 | $214.32 Million | -58.58% |
| 2018 | $517.41 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Equillium Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $89.41 Million USD |
| MoneyControl | $89.41 Million USD |
| MarketWatch | $89.41 Million USD |
| marketcap.company | $89.41 Million USD |
| Reuters | $89.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 fo… Read more